Atara Biotherapeutics (ATRA) Common Equity (2013 - 2026)

Atara Biotherapeutics' Common Equity history runs 14 years deep, the most recent figure standing at -$37.3 million for Q1 2026.

• Quarterly Common Equity rose 32.25% year-over-year to -$37.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.3 million (up 32.25% YoY) and the FY2025 annual result came in at -$38.5 million, up 60.42% from the prior year.
• Common Equity was -$37.3 million for Q1 2026 at Atara Biotherapeutics, up from -$38.5 million in the prior quarter.
• Across five years, Common Equity topped out at $257.5 million in Q2 2022 and bottomed at -$110.9 million in Q2 2024.
• A 5-year average of $18.6 million and a median of -$36.6 million in 2025 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2024 — Common Equity plunged 1587.36% — and 2025, when it surged 68.39%.
• Atara Biotherapeutics' Common Equity stood at $126.6 million in 2022, then decreased by 21.64% to $99.2 million in 2023, then slumped by 198.04% to -$97.3 million in 2024, then jumped by 60.42% to -$38.5 million in 2025, then rose by 3.09% to -$37.3 million in 2026.
• Business Quant data shows ATRA's Common Equity at -$37.3 million in Q1 2026, -$38.5 million in Q4 2025, and -$36.6 million in Q3 2025.